Pembrolizumab: tested with established drugs

245 studies: they are given beside it. Page 2 of 3. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)CompletedNCT03036488Phase 3Results postedReport a problem
• Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT03029598Phase 1/2Results postedReport a problem
• Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast CancerCompletedNCT03018080Phase 2Results postedReport a problem
• Study of Pembrolizumab in Locally Advanced Esophageal AdenocarcinomaActive, not recruitingNCT02998268Phase 2Results postedReport a problem
• Interleukin-2 and Pembrolizumab for Metastatic Kidney CancerCompletedNCT02964078Phase 2Results postedReport a problem
• Pembrolizumab vs Topotecan in Patients With Small Cell Lung CancerTerminatedNCT02963090Phase 2Results postedReport a problem
• Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) CancerCompletedNCT02954536Phase 2Results postedReport a problem
• Pembrolizumab (MK-3475) in Hepatocellular CarcinomaCompletedNCT02940496Phase 2Results postedReport a problem
• Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)TerminatedNCT02934503Phase 2Results postedReport a problem
• Perioperative Chemo and Pembrolizumab in Gastric CancerCompletedNCT02918162Phase 2Results postedReport a problem
• Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantCompletedNCT02880228Phase 2Results postedReport a problem
• Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)CompletedNCT02853305Phase 3Results postedReport a problem
• Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older PatientsCompletedNCT02845297Phase 2Results postedReport a problem
• Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).TerminatedNCT02834975Phase 2Results postedReport a problem
• PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckTerminatedNCT02819752Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)CompletedNCT02819518Phase 3Results postedReport a problem
• Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerCompletedNCT02808143Phase 1Results postedReport a problem
• Pembrolizumab in Patients With Advanced Malignant Pleural MesotheliomaCompletedNCT02784171Phase 2/3Results postedReport a problem
• Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerActive, not recruitingNCT02778685Phase 2Results postedReport a problem
• Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck CancerCompletedNCT02777385Phase 2Results postedReport a problem
• A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)CompletedNCT02775435Phase 3Results postedReport a problem
• Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary CancerCompletedNCT02766582Phase 2Results postedReport a problem
• A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell CarcinomaCompletedNCT02759575Phase 1/2Results postedReport a problem
• Standard of Care Chemotherapy Plus Pembrolizumab for Breast CancerActive, not recruitingNCT02734290Phase 1/2Results postedReport a problem
• Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by SurgeryCompletedNCT02730546Phase 1/2Results postedReport a problem
• Genetic Predictors of Benefit to PembrolizumabTerminatedNCT02710396Phase 2Results postedReport a problem
• Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin CancerCompletedNCT02690948Phase 1/2Results postedReport a problem
• Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder CancerCompletedNCT02662062Phase 2Results postedReport a problem
• Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast CancerCompletedNCT02648477Phase 2Results postedReport a problem
• Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT02641093Phase 2Results postedReport a problem
• Pembrolizumab and Chemoradiation Treatment for Advanced Cervical CancerCompletedNCT02635360Phase 2Results postedReport a problem
• MK-3475 Immunotherapy in Endometrial CarcinomaCompletedNCT02630823Phase 1Results postedReport a problem
• Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung CancerCompletedNCT02621398Phase 1Results postedReport a problem
• Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the BladderCompletedNCT02621151Phase 2Results postedReport a problem
• A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian CancerCompletedNCT02608684Phase 2Results postedReport a problem
• Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerCompletedNCT02595866Phase 1Results postedReport a problem
• Pembrolizumab in Combination With CRT for LA-SCCHNCompletedNCT02586207Phase 1Results postedReport a problem
• Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)TerminatedNCT02579863Phase 3Results postedReport a problem
• Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)CompletedNCT02578680Phase 3Results postedReport a problem
• Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)TerminatedNCT02576977Phase 3Results postedReport a problem
• MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer PatientsCompletedNCT02574598Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)CompletedNCT02563002Phase 3Results postedReport a problem
• Pembro/Carbo/Taxol in Endometrial CancerCompletedNCT02549209Phase 2Results postedReport a problem
• Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular LymphomaCompletedNCT02541565Phase 1Results postedReport a problem
• Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02520154Phase 2Results postedReport a problem
• Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)CompletedNCT02494583Phase 3Results postedReport a problem
• Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate CancerCompletedNCT02489357Not applicableResults postedReport a problem
• Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian CancerCompletedNCT02440425Phase 2Results postedReport a problem
• MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT02422381Phase 1/2Results postedReport a problem
• Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung CancerCompletedNCT02402920Phase 1Results postedReport a problem
• Reversing Therapy Resistance With Epigenetic-Immune ModificationTerminatedNCT02395627Phase 2Results postedReport a problem
• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCTerminatedNCT02382406Phase 1/2Results postedReport a problem
• Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal CancerCompletedNCT02375672Phase 2Results postedReport a problem
• Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC SubjectsCompletedNCT02365766Phase 1/2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)CompletedNCT02358031Phase 3Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)CompletedNCT02335411Phase 2Results postedReport a problem
• Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple MyelomaCompletedNCT02331368Phase 2Results postedReport a problem
• MK-3475/BCG in High Risk Superficial Bladder CancerCompletedNCT02324582Phase 1Results postedReport a problem
• Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade GliomasCompletedNCT02313272Phase 1Results postedReport a problem
• Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With EnzalutamideCompletedNCT02312557Phase 2Results postedReport a problem
• Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT02296684Phase 2Results postedReport a problem
• 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT02289222Phase 1/2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)CompletedNCT02039674Phase 1/2Results postedReport a problem
• A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)TerminatedNCT02036502Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)CompletedNCT01840579Phase 1Results postedReport a problem
• Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)CompletedNCT01704287Phase 2Results postedReport a problem
• A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)Active, not recruitingNCT06698042Phase 3Report a problem
• EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaActive, not recruitingNCT06556563Phase 3Report a problem
• Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerWithdrawnNCT06528210Phase 2Report a problem
• A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)Active, not recruitingNCT06504394Phase 2Report a problem
• PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STSCompletedNCT06413095Early Phase 1Report a problem
• A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLCTerminatedNCT06280196Phase 3Report a problem
• Pembrolizumab Followed by Chemotherapy for the Treatment of Patients With Classical Hodgkin LymphomaActive, not recruitingNCT06164275Phase 2Report a problem
• Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)Active, not recruitingNCT06155279Phase 2Report a problem
• Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung CancerTerminatedNCT06140407Phase 2Report a problem
• A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Active, not recruitingNCT06041802Phase 2Report a problem
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3Report a problem
• A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast CancerStatus unknownNCT05681728Phase 2Report a problem
• Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.Active, not recruitingNCT05563467Phase 2Report a problem
• Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric CancerActive, not recruitingNCT05508737Phase 1/2Report a problem
• Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT05302011Phase 2Report a problem
• Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingNCT05221645Phase 2Report a problem
• A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)CompletedNCT05017012Phase 1Report a problem
• Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')Status unknownNCT04946227Phase 2Report a problem
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)Active, not recruitingNCT04895358Phase 3Report a problem
• Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China ExtensionWithdrawnNCT04859582Phase 3Report a problem
• Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)Active, not recruitingNCT04634877Phase 3Report a problem
• Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA MutationsActive, not recruitingNCT04548752Phase 2Report a problem
• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal CancerCompletedNCT04522336Phase 1Report a problem
• Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic CancerActive, not recruitingNCT04447092Phase 2Report a problem
• Cisplatin+Pembrolizumab+RT in Vulvar CancerActive, not recruitingNCT04430699Phase 2Report a problem
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04387227Phase 2Report a problem
• Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal CancerCompletedNCT04357587Phase 1Report a problem
• Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive, not recruitingNCT04340882Phase 2Report a problem
• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)Active, not recruitingNCT04241185Phase 3Report a problem
• Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical CancerStatus unknownNCT04238988Phase 2Report a problem
• Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile CancerCompletedNCT04224740Phase 2Report a problem
• Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Phase 3Report a problem
• Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompletedNCT04201873Phase 1Report a problem
• HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck CancerCompletedNCT04188951Early Phase 1Report a problem

← Pembrolizumab